You just read:

Microbiotix and the AMR Centre Announce Co-Development Agreement Targeting Drug Resistant P. aeruginosa in Critically Ill Pneumonia Patients

News provided by

Microbiotix, Inc.

14 Sep, 2017, 21:17 BST